Tulsa, OKNCT06533748Now EnrollingIRB Ready

Acute Lymphoblastic Leukemia Clinical Trial in Tulsa, OK

Access cutting-edge acute lymphoblastic leukemia treatment through this phase 2 clinical trial at a research site in Tulsa. Study-provided care at no cost to qualified participants.

Sponsored by St. Jude Children's Research Hospital

Quick Self-Assessment

See if you qualify for this Tulsa location

Preparing your pre-screening questions…

Expert Care in Tulsa

Access acute lymphoblastic leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute lymphoblastic leukemia treatment provided free

Apply for This Tulsa Location

Check if you qualify for this acute lymphoblastic leukemia clinical trial in Tulsa, OK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tulsa

    Convenient for OK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tulsa site if eligible
  4. 4Begin participation

About This Acute Lymphoblastic Leukemia Study in Tulsa

This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma. Primary Objective * To assess if the flow-cytometry assessed MRD-negative remission rate following an immunotherapy-based Induction in NCI-high risk patients without favorable genetic features is higher than the results of similar patients trea

Sponsor: St. Jude Children's Research Hospital

Who Can Participate

Inclusion Criteria

Enrollment on INITIALL.
Age 1-18.99 years at the time of enrollment on INITIALL.
B-Acute lymphoblastic leukemia or lymphoblastic lymphoma.
No prior chemotherapy excluding therapy given on or allowed by INITIALL.
NCI high-risk (age 10 years or greater or presenting WBC count ≥50,000 cells/microL) or NCI standard-risk and a HR clinical feature as listed below:
CNS3 disease (≥5 WBC/microL CSF with blasts present)
Testicular involvement of leukemia
Steroid pretreatment defined as \>24 hours of therapy in the 14 days prior to enrollment on INITIALL if a preceding WBC to define NCI risk is unavailable
For lymphoblastic lymphoma, Stage 3-4 disease OR Stage 1-2 disease in patient ages ≥10 years OR HR clinical feature as defined above.
Adequate liver function defined as:
Total bilirubin ≤ 1.5x the upper limit of normal for age and alanine transaminase (ALT) ≤ 5x the upper limit of normal for age. Patients with an elevated total bilirubin due to hemolysis are eligible if they have a direct bilirubin \<1.5x the upper limit of normal.
Adequate renal function defined as:
Calculated glomerular filtration rate (GFR) ≥ 50 mL/min/1.73m\^2 using the Bedside Schwartz equation OR creatinine below or equal to the maximum defined below:
Age: 1 to \<2 years; maximum serum creatinine (mg/dL): 0.6 (male and female)
Age: 2 to \<6 years; maximum serum creatinine (mg/dL): 0.8 (male and female)
Age: 6 to \<10 years; maximum serum creatinine (mg/dL): 1.0 (male and female)
Age: 10 to \<13 years; maximum serum creatinine (mg/dL): 1.2 (male and female)
Age: 13 to \<16 years; maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)
Age: ≥16 years; maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)
Eligibility for inclusion post-induction requires meeting the first 4 Inclusion criteria above AND:
Treatment on SJALL23H for Induction OR
Lymphoblastic lymphoma, initially treated on an SJALL protocol OR standard (non-protocol) therapy, without a complete response at the end of induction OR
NCI-SR ALL at diagnosis and treated with an SJALL protocol OR standard (non-protocol) therapy who have
Slow response to therapy (≥0.1% MRD at end of induction for patients with hyperdiploid ALL or ≥0.01% MRD at end of induction for others with ALL) OR
HR genetics as defined in the protocol.
These patients may receive no more than 2 weeks of post-induction therapy and should be transitioned to SJALL23H post-induction as soon as the qualifying genetic or MRD result is available.

Exclusion Criteria

Presence of ETV6::RUNX1 fusion unless also having a HR clinical feature OR slow response to induction therapy.
History or presence of clinically relevant central nervous system (CNS) pathology or event such as epilepsy, childhood or adult non-febrile seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. History of simple febrile seizure during childhood and presence of CNS leukemia at diagnosis are not exclusions to participation.
Active uncontrolled infection.
Current active autoimmune disease or history of autoimmune disease with the potential for CNS involvement.
History of venoocclusive disease/ sinusoidal obstructive syndrome.
Unstable cardiac disease including QTc \>500msec.
Inability or unwillingness to give informed consent/ assent as applicable.
Pregnant or lactating.
For patients of reproductive potential, unwillingness to use effective contraception for the duration of protocol therapy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tulsa?

Yes, this clinical trial (NCT06533748) has an active research site in Tulsa, OK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Lymphoblastic Leukemia Treatment Options in Tulsa, OK

If you're searching for acute lymphoblastic leukemia treatment options in Tulsa, OK, this clinical trial (NCT06533748) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tulsa research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced acute lymphoblastic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute lymphoblastic leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Tulsa, OK

See all leukemia clinical trials recruiting in Tulsa — not just this study.

Browse Leukemia Trials in Tulsa →

Browse More Trials by Condition

Leukemia TrialsB-Cell Acute Lymphoblastic Leukemia TrialsHeart Attack TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Tulsa?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tulsa, OK